DK2403845T3 - Forbedret proces. - Google Patents

Forbedret proces.

Info

Publication number
DK2403845T3
DK2403845T3 DK10707950.1T DK10707950T DK2403845T3 DK 2403845 T3 DK2403845 T3 DK 2403845T3 DK 10707950 T DK10707950 T DK 10707950T DK 2403845 T3 DK2403845 T3 DK 2403845T3
Authority
DK
Denmark
Prior art keywords
improved process
improved
Prior art date
Application number
DK10707950.1T
Other languages
Danish (da)
English (en)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Shreyas Shrikant Bhandari
Suresh Hasbe
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Application granted granted Critical
Publication of DK2403845T3 publication Critical patent/DK2403845T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Glass Compositions (AREA)
DK10707950.1T 2009-03-02 2010-03-01 Forbedret proces. DK2403845T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
DK2403845T3 true DK2403845T3 (da) 2014-08-04

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10707950.1T DK2403845T3 (da) 2009-03-02 2010-03-01 Forbedret proces.

Country Status (16)

Country Link
US (1) US8946265B2 (https=)
EP (1) EP2403845B1 (https=)
JP (1) JP5727944B2 (https=)
CN (1) CN102414196A (https=)
AU (1) AU2010220204B2 (https=)
CA (1) CA2753241C (https=)
CY (1) CY1115376T1 (https=)
DK (1) DK2403845T3 (https=)
ES (1) ES2487215T3 (https=)
HR (1) HRP20140686T1 (https=)
NZ (1) NZ595492A (https=)
PL (1) PL2403845T3 (https=)
PT (1) PT2403845E (https=)
SI (1) SI2403845T1 (https=)
SM (1) SMT201400100B (https=)
WO (1) WO2010100476A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
WO2011111053A1 (en) * 2010-03-08 2011-09-15 Natco Pharma Limited Anhydrous lenalidomide form-i
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
US9540341B2 (en) 2011-07-19 2017-01-10 Amplio Pharma, Llc Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
WO2014155371A2 (en) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Crystalline lenalidomide process
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
EP3183244B1 (en) * 2014-08-19 2019-04-10 Synthon BV Process for making crystalline form a of lenalidomide
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017109041A1 (en) * 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
EP3687987A4 (en) * 2017-09-27 2021-03-24 Biocon Limited CRYSTALLINE FORMS OF LENALIDOMIDE
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体(上海)有限公司 一种制备来那度胺的方法
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
BRPI0514865A (pt) * 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
US8304250B2 (en) 2007-04-16 2012-11-06 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
CA2709262A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited New hplc method
CA2717326C (en) 2008-03-11 2018-10-23 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2010061209A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
CA2753241C (en) 2015-06-16
AU2010220204B2 (en) 2015-10-08
SI2403845T1 (sl) 2014-09-30
PL2403845T3 (pl) 2014-09-30
US8946265B2 (en) 2015-02-03
CY1115376T1 (el) 2017-01-04
ES2487215T3 (es) 2014-08-20
WO2010100476A2 (en) 2010-09-10
PT2403845E (pt) 2014-08-04
SMT201400100B (it) 2014-11-10
NZ595492A (en) 2013-07-26
JP5727944B2 (ja) 2015-06-03
US20120071509A1 (en) 2012-03-22
JP2012519207A (ja) 2012-08-23
EP2403845A2 (en) 2012-01-11
HRP20140686T1 (hr) 2014-09-26
CN102414196A (zh) 2012-04-11
WO2010100476A3 (en) 2011-06-16
AU2010220204A1 (en) 2011-10-20
EP2403845B1 (en) 2014-04-30
CA2753241A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
DK2403845T3 (da) Forbedret proces.
HRP20210923T8 (hr) Poboljšani proces predtretiranja biomase
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
DK2401047T3 (da) Separationsfremgangsmåde
BRPI1011965A2 (pt) estrutura de entressola.
BRPI1014053A2 (pt) aparelho de moldagem.
BRPI1006166A2 (pt) gestos padrão.
BR112013030877A2 (pt) processamento de biomassa.
HUE049112T2 (hu) Depolimerizálási eljárás
BR112012000822A2 (pt) processo
BR112012012338A2 (pt) processo
FR2947376B1 (fr) Sectionneur.
EP2457154A4 (en) MULTIPLEXING WITH PSEUDO-SYNCHRONOUS DISTRIBUTION IN TIME
BRPI1014802A2 (pt) pró-fármacos de triptolida.
IT1396487B1 (it) Convogliatore.
PL2561040T3 (pl) Proces produkcji biopaliwa
BRPI1010553A2 (pt) processo de carbonilação.
BRPI1012134A2 (pt) processo de carbolinação
BRPI1007573A2 (pt) processo
BRPI1008708A2 (pt) gastroscópio.
IT1397885B1 (it) Processo per preparare etilbenzene.
BR112012003642A2 (pt) processo
BRPI1011014A2 (pt) método de produção.
IT1399912B1 (it) Processo di preparazione di ritodrina cloridrato.
BRPI1011571A2 (pt) Processo